SMS Pharmaceuticals has informed that Board of Directors of the Company at their meeting held on today considered and approved the: Standalone and Consolidated Un-audited Financial Results for the Quarter ended 30th June, 2021 along with the Limited Review Report, Reclassification of promoter group shareholding from promoter category to public category, Directors Report by the Board for the FY 2020-21, Convening the 33rd Annual General Meeting on 30th, September, 2021 and Dividend Distribution Policy. Accordingly, the company has enclosed the following: Reclassification of Promoter group shareholding from promoter category to public category and Standalone and Consolidated un-audited Financial Results for the quarter ended 30th June, 2021 along with the Limited Review Report. The meeting commenced at 10.30 am and concluded at 12.30 pm.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: